CLI Responds to Halting of Abortion Pill Trial
Scholar Says Failed Trial Only Underscores Danger of Medication Abortion
Today, the Charlotte Lozier Institute (CLI), the research and education arm of Susan B. Anthony List, issued the following statement in response to a report that researchers suspended a trial concerning the abortion pill reversal protocol:
“Pro-abortion researchers would rather continue to mislead women about the real risks of the abortion pill regimen Mifeprex than protect them from the risks of this dangerous drug,” said Dr. Tara Sander Lee, CLI’s Senior Fellow and Director of Life Sciences.
“Long before this study was published, it was a known fact that Mifeprex can cause serious and sometimes fatal infections, excessive bleeding, and incomplete termination requiring follow-up surgery. This study does nothing but further prove these serious, life-threatening risks when taking the abortion pill.
“The study was ended early because of severe hemorrhage in 25% (3 out of 12) of women, requiring emergency ambulatory care, because they took the abortion pill. Even the authors highlight that this is a rate much higher (42% higher) than previously reported. In fact, the bleeding was so bad for one woman, described as ‘significant brisk bleeding,’ that she needed a blood transfusion. She also developed hypotension and tachycardia.
“Of the three women that required ambulatory care, two had received a placebo and one had taken progesterone.
“Instead of focusing on the facts that the abortion pill is dangerous, the attempt here is to mislead the public into believing that any attempt to reverse the abortion pill and delay killing the baby could be potentially more dangerous to the mother – when, in fact, their study did show that a heartbeat was detected at the first follow-up visit in 80 percent of women who attempted to reverse the abortion pill. And in fact, both women who hemorrhaged while on placebo required emergency surgical aspiration, but the woman on progesterone did not require any additional intervention.”
CLI President Chuck Donovan added:
“Because of these serious risks to women, the FDA must more tightly regulate the dangerous abortion pill use and keep Mifeprex on the REMS list.”
CLI experts have previously criticized flawed research purporting to show that self-administered, self-reported chemical abortions are not dangerous women.
AbortionDrugFacts.com, a new website developed with input from CLI’s team of experts and pro-life partners, aims to give women the information they need to protect their health and safety before they go through a chemical abortion, to have a second chance to change their mind after initiating one or to recover from the trauma they may already have experienced as a result of taking abortion drugs. In addition, the site provides women who have been hurt by the abortion pill an opportunity to share their story and/or make a confidential report to the FDA.
Charlotte Lozier Institute was launched in 2011 as the education and research arm of Susan B. Anthony List. CLI is a hub for research and public policy analysis on some of the most pressing issues facing the United States and nations around the world. The Institute is named for a feminist physician known for her commitment to the sanctity of human life and equal career and educational opportunities for women.